gefitinib

gefitinib

美 　英

• 網絡吉非替尼；易瑞沙；吉菲特尼

例句

Gefitinib failed to show superiority to placebo as second- or third-line treatment, but it has been shown to be non inferior to docetaxel.

吉非替尼在二線和三線治療中與安慰劑相比無優勢，但其作用不遜于多西他賽。

However, this specific mutation did not cause acne, another side of effect of gefitinib.

然而，這種特異性的突變不會導致gefitinib的另一個副作用：痤瘡。

Gefitinib may have inhibitory effects against bone resorption as well as antitumor effects.

吉非替尼可能會抑制對骨吸收以及抗腫瘤作用。

Being female was also significantly associated with response to gefitinib.

病人是女性也與對吉非替尼有反應顯著相關。

The acute toxicity of gefitinib up to 500 mg in clinical studies has been low.

急性毒性吉非替尼多達500毫克的臨床研究一直很低。

Doctor, the profile that you just read is actually for (gefitinib) IRESSA.

醫生，剛才您所閱讀的簡介其實就是（吉非替尼）易瑞沙。

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

肺癌中表皮生長因子受體突變：吉非替尼治療的臨床反應。

What are your first thoughts about the potential indication for IRESSA (gefitinib) IRESSA? Do you agree? Do you think it is appropriate?

對于易瑞沙（吉非替尼）的潛在跡象有什么想法？您是否贊同？您認為它是否合適？

The advantages that Gefitinib treated non-small cell lung cancer and the existing problems were expounded in this thesis.

本文針對吉非替尼靶向治療非肺癌小細胞肺癌中的優點和所面臨的問題進行闡述。

We reported cases of non-small-cell lung cancer who had dramatic improvements of pathologic fractures with gefitinib.

我們報告的非小細胞肺癌有顯著改善誰的病理性骨折與吉非替尼。

Results 31 patients with Gefitinib associated skin rash were divided Wind-Heat type, Damp-Heat type, Blood-Heat type and Blood-XU type.

結果31例吉非替尼相關皮疹患者，辨證分型為：風熱型、濕熱型、血熱型、陰虛型；

Therefore, it would also provide necessary evidence to test EGFR mutations for the use of Gefitinib in CRCs.

因此，檢測大腸癌EGFR外顯子突變也為將吉非替尼療應用于大腸癌提供理論依據。

A phase II study evaluated gefitinib and docetaxel as second-line therapy .

一項II期臨床試驗對gefitinib和多西他賽作為二線治療方案進行檢驗。

Clinical observation on advanced stage adenocarcinoma of lung treated with gefitinib after failure of chemotherapy

吉非替尼治療化療失敗晚期肺腺癌的臨床觀察

Gefitinib in patients with advanced refractory small cell lung cancer contemporaneous with superior vena cava syndrome

吉非替尼治療晚期難治性小細胞肺癌合并急性上腔靜脈綜合征

Efficacy of Gefitinib on Chinese Patients with Locally Advanced or Metastatic Non-small Cell Lung Cancer: a Clinical Trial

吉非替尼治療局部晚期或轉移性非小細胞肺癌在中國的臨床研究

Overview of relationship between EGFR gene mutation and efficacy and acquired drug resistance of gefitinib

EGFR基因突變與吉非替尼的療效和獲得性耐藥關系的研究概況

Effect of EGFR inhibitor gefitinib on proliferation and apoptosis of hepatocellular carcinoma cells

EGFR抑制劑吉非替尼對肝癌細胞增殖和凋亡的影響

Preliminary observation of gefitinib in salvage treatment of patients with previouslytreated, advanced non-small cell lung cancer

吉非替尼挽救性治療晚期非小細胞肺癌的初步觀察

Gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor

表皮生長因子受體酪氨酸激酶抑制劑吉非替尼

Efficacy of Gefitinib on Advanced Non-small Cell Lung Cancer of Bilateral Diffuse or Unilateral Giant Mass Type

吉非替尼治療不同類型晚期非小細胞肺癌患者的療效比較

Oral gefitinib is small molecular targeted therapeutic drug

口服小分子靶向治療藥物吉非替尼

Gefitinib in elderly and unfit patients affected non-small-cell lung cancer

吉非替尼在老年和行為狀態差的非小細胞肺癌患者中的應用

Targeted therapy with gefitinib for non-small cell lung cancer

吉非替尼靶向治療非小細胞肺癌

Progress in research of gefitinib, an anticancer drug

抗腫瘤藥物吉非替尼的研究進展

An improved synthetic process for gefitinib

吉非替尼的合成工藝改進

Gefitinib in the treatment of advanced, refractory non-small cell lung cancer: EAP study in 53 patients

吉非替尼治療晚期非小細胞肺癌53例臨床觀察

Progress in therapy of gefitinib for Non-small cell lung cancer

吉非替尼治療非小細胞肺癌的研究進展